Proposed definitions of antibody-mediated rejection for use as a clinical trial endpoint in kidney transplantation

Proposed definitions of antibody-mediated rejection for use as a clinical trial endpoint in kidney transplantation

Antibody-mediated rejection (AMR) is caused by antibodies that recognize donor human leukocyte antigen (HLA) or other targets. As knowledge of AMR pathophysiology has increased, a combination of factors is necessary to confirm the diagnosis and phenotype. However, frequent modifications to the AMR d...

Detaylı Bibliyografya
Asıl Yazarlar:	Roufosse, C, Becker, JU, Rabant, M, Seron, D, Bellini, MI, Böhmig, GA, Budde, K, Diekmann, F, Glotz, D, Hilbrands, L, Loupy, A, Oberbauer, R, Pengel, L, Schneeberger, S, Naesens, M
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	Frontiers Media 2022

Benzer Materyaller

Proposed definitions of T cell-mediated rejection and tubulointerstitial inflammation as clinical trial endpoints in kidney transplantation
Yazar:: Seron, D, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Rationale for surrogate endpoints and conditional marketing authorization of new therapies for kidney transplantation
Yazar:: Naesens, M, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Allograft function as endpoint for clinical trials in kidney transplantation
Yazar:: Hilbrands, L, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Alloimmune risk stratification for kidney transplant rejection
Yazar:: Bestard, O, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Patient-reported outcomes as endpoints in clinical trials of kidney transplantation interventions
Yazar:: Tong, A, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Skip Soft Definitions and Focus on Hard Endpoints∗
Yazar:: Juan C. Lopez-Mattei, MD, ve diğerleri
Baskı/Yayın Bilgisi: (2019-12-01)

2017 cardiovascular and stroke endpoint definitions for clinical trials
Yazar:: Hicks, KA, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
Yazar:: Hicks, KA, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials
Yazar:: Ciani, O, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Surrogate Endpoint Evaluation: Principal Stratification Criteria and the Prentice Definition
Yazar:: Gilbert Peter B., ve diğerleri
Baskı/Yayın Bilgisi: (2015-09-01)

The Role of the Endothelium during Antibody-Mediated Rejection: From Victim to Accomplice
Yazar:: Amy Rachael Cross, ve diğerleri
Baskı/Yayın Bilgisi: (2018-01-01)

Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition.
Yazar:: Harris, P, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Current variables, definitions and endpoints of the European Cardiovascular Magnetic Resonance Registry
Yazar:: Schwitter Juerg, ve diğerleri
Baskı/Yayın Bilgisi: (2009-11-01)

Digital Endpoints: Definition, Benefits, and Current Barriers in Accelerating Development and Adoption
Yazar:: Matthew Landers, ve diğerleri
Baskı/Yayın Bilgisi: (2021-09-01)

Early Estimated Glomerular Filtration Rate Trajectories After Kidney Transplant Biopsy as a Surrogate Endpoint for Graft Survival in Late Antibody-Mediated Rejection
Yazar:: Anita Borski, ve diğerleri
Baskı/Yayın Bilgisi: (2022-04-01)

European Consensus on the Management of Sensitized Kidney Transplant Recipients: A Delphi Study
Yazar:: Lucrezia Furian, ve diğerleri
Baskı/Yayın Bilgisi: (2024-04-01)

Trial design and end points in clinical transplant research
Yazar:: Knight, S, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Antibody Mediated Rejection and T-cell Mediated Rejection Molecular Signatures Using Next-Generation Sequencing in Kidney Transplant Biopsies
Yazar:: Esteban Cortes Garcia, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Refinement of Animal Model of Colorectal Carcinogenesis through the Definition of Novel Humane Endpoints
Yazar:: Rita Silva-Reis, ve diğerleri
Baskı/Yayın Bilgisi: (2021-04-01)

A framework for the definition and interpretation of the use of surrogate endpoints in interventional trialsResearch in context
Yazar:: Oriana Ciani, ve diğerleri
Baskı/Yayın Bilgisi: (2023-11-01)

A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials
Yazar:: N. K. Hills, ve diğerleri
Baskı/Yayın Bilgisi: (2021-08-01)

How to Treat T Cell Mediated Rejection? -A Call for Action
Yazar:: Klemens Budde
Baskı/Yayın Bilgisi: (2024-04-01)

Deciphering the Complexity of the Immune Cell Landscape in Kidney Allograft Rejection
Yazar:: George Terinte-Balcan, ve diğerleri
Baskı/Yayın Bilgisi: (2024-12-01)

How TAVI registries report clinical outcomes-A systematic review of endpoints based on VARC-2 definitions.
Yazar:: Shixuan Zhang, ve diğerleri
Baskı/Yayın Bilgisi: (2017-01-01)

Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema.
Yazar:: Lassere, M, ve diğerleri
Baskı/Yayın Bilgisi: (2007)

PB2508: COMPARING DEFINITIONS OF EPISODES OF VASO-OCCLUSION AS ENDPOINTS IN CLINICAL STUDIES OF SICKLE CELL DISEASE
Yazar:: Franco Locatelli, ve diğerleri
Baskı/Yayın Bilgisi: (2023-08-01)

Real-Time High Definition License Plate Localization and Recognition Accelerator for IoT Endpoint System on Chip
Yazar:: Shizhen Huang, ve diğerleri
Baskı/Yayın Bilgisi: (2021-10-01)

Endpoint security /
Yazar:: 215290 Kadrich, Mark
Baskı/Yayın Bilgisi: (2007)

To and the construction of endpoints
Yazar:: Lise Hamelin
Baskı/Yayın Bilgisi: (2012-12-01)

European Survey on Clinical Practice of Detecting and Treating T-Cell Mediated Kidney Transplant Rejection
Yazar:: Priyanka Koshy, ve diğerleri
Baskı/Yayın Bilgisi: (2024-04-01)

Calcium affects on vascular endpoints
Yazar:: Patel Vaishali B, ve diğerleri
Baskı/Yayın Bilgisi: (2012-03-01)

Interpretation of composite endpoints in Urology
Yazar:: C.F.S. Jensen, ve diğerleri
Baskı/Yayın Bilgisi: (2020-07-01)

Summary of Scientific and Statistical Methods, Study Endpoints and Definitions for Observational and Registry-Based Studies in Hematopoietic Cell Transplantation
Yazar:: Abraham S. Kanate, ve diğerleri
Baskı/Yayın Bilgisi: (2019-12-01)

Comparison of an ordinal endpoint to time-to-event, longitudinal, and binary endpoints for use in evaluating treatments for severe influenza requiring hospitalization
Yazar:: Ross L. Peterson, ve diğerleri
Baskı/Yayın Bilgisi: (2019-09-01)

Biomarkers and surrogate endpoints.
Yazar:: Aronson, J
Baskı/Yayın Bilgisi: (2005)

The endpoint of partial deconfinement
Yazar:: David Berenstein, ve diğerleri
Baskı/Yayın Bilgisi: (2023-12-01)

Biomarker endpoints in cancer cachexia clinical trials: Systematic Review 5 of the cachexia endpoint series
Yazar:: Michael S. Yule, ve diğerleri
Baskı/Yayın Bilgisi: (2024-06-01)

Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial
Yazar:: Farsad Eskandary, ve diğerleri
Baskı/Yayın Bilgisi: (2019-01-01)

Opinions on the Future of Clinical Pig Kidney Xenotransplantation
Yazar:: Georg A. Böhmig, ve diğerleri
Baskı/Yayın Bilgisi: (2024-11-01)

How good is a living donor? Systematic review and meta-analysis of the effect of donor demographics on post kidney transplant outcomes
Yazar:: Bellini, MI, ve diğerleri
Baskı/Yayın Bilgisi: (2022)